Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Juan Fortea, Eduard Vilaplana, María Carmona‐Iragui, +26

The Lancet

APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease

Juan Fortea, Jordi Pegueroles, Daniel Alcolea, +11

Nature Medicine

Neurodegenerative DiseasesAlzheimer's DiseaseGeneticsDegenerative PathologyNeurology +5

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Juan Fortea, María Carmona‐Iragui, Bessy Benejam, +16

The Lancet Neurology

Down SyndromeAlzheimer's DiseaseCsf BiomarkersDementiaBiomarkers +9

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders

Daniel Alcolea, Jordi Clarimón, María Carmona‐Iragui, +38

Alzheimer s & Dementia Translational Research & Clinical Interventions

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

Constance Delaby, Daniel Alcolea, María Carmona‐Iragui, +23

Scientific Reports

Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal‐dominant Alzheimer's disease

María Carmona‐Iragui, Mircea Balasa, Bessy Benejam, +22

Alzheimer s & Dementia

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

Nuole Zhu, Miguel Santos‐Santos, Ignacio Illán‐Gala, +18

Translational Neurodegeneration

Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings

Sandra Giménez, Laura Videla, Sergio Romero, +18

Journal of Clinical Sleep Medicine

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome

Alexandre Bejanin, M. Florencia Iulita, Eduard Vilaplana, +32

JAMA Neurology

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone

Constance Delaby, Teresa Estellés, Nuole Zhu, +19

Alzheimer s Research & Therapy